# Lexaria Bioscience Corp. (LEXX)

Source: https://www.quantisnow.com/company/LEXX
Generated: 2026-11-16T05:14:49.450Z

- Ticker: LEXX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001348362
- Website: lexariabioscience.com

## About

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.

## Latest LEXX news and filings

- 2026-11-04 14:00 UTC [Market Insight] [Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH](https://www.quantisnow.com/insight/lexaria-enters-a-new-pharmaceutical-agreement-for-dehydratech-6771638)
- 2026-10-28 13:10 UTC [Market Insight] [Lexaria Celebrates its 70th Patent Award](https://www.quantisnow.com/insight/lexaria-celebrates-its-70th-patent-award-6760799)
- 2026-10-21 13:25 UTC [Market Insight] [Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule](https://www.quantisnow.com/insight/lexarias-human-study-glp-1-h26-7-reaches-full-enrollment-and-continues-dosing-6753192)
- 2026-10-15 13:10 UTC [Market Insight] [Lexaria Announces Results from Animal Study GLP-1-A26-1](https://www.quantisnow.com/insight/lexaria-announces-results-from-animal-study-glp-1-a26-1-6747593)
- 2026-10-14 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Lexaria Bioscience Corp.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-lexaria-bioscience-corp-6745749)
- 2026-10-13 21:15 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Lexaria Bioscience Corp.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-lexaria-bioscience-corp-6745443)
- 2026-10-06 13:10 UTC [Market Insight] [GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications](https://www.quantisnow.com/insight/glp-1-weight-lossdiabetes-industries-continue-transition-to-oral-medications-6738496)
- 2026-10-02 01:17 UTC [SEC Form S-3] [SEC Form S-3 filed by Lexaria Bioscience Corp.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-lexaria-bioscience-corp-6733370)
- 2026-09-17 13:10 UTC [Market Insight] [Lexaria Updates Financial Position](https://www.quantisnow.com/insight/lexaria-updates-financial-position-6718681)
- 2026-09-09 20:15 UTC [Market Insight] [Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds](https://www.quantisnow.com/insight/lexaria-announces-closing-of-exercise-of-warrants-for-approximately-59-6710049)
- 2026-09-09 14:12 UTC [SEC Form 8-K] [Lexaria Bioscience Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lexaria-bioscience-corp-filed-sec-form-8-k-entry-into-a-6709730)
- 2026-09-08 12:00 UTC [Market Insight] [Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds](https://www.quantisnow.com/insight/lexaria-announces-exercise-of-warrants-for-approximately-59-million-in-6707608)
- 2026-09-04 13:20 UTC [Market Insight] [Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/lexaria-to-present-at-the-hc-wainwright-28th-annual-global-6706365)
- 2026-09-01 13:16 UTC [SEC Form 8-K] [Lexaria Bioscience Corp. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/lexaria-bioscience-corp-filed-sec-form-8-k-other-events-6700894)
- 2026-09-01 13:15 UTC [Market Insight] [Lexaria Receives USD$2.6 Million Tax Rebate Payment](https://www.quantisnow.com/insight/lexaria-receives-usd26-million-tax-rebate-payment-6700889)
- 2026-08-24 13:10 UTC [Market Insight] [DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2](https://www.quantisnow.com/insight/dehydratechtm-enhanced-amycretin-and-retatrutide-yield-significant-absorption-improvements-in-lexarias-6692308)
- 2026-08-17 16:37 UTC [SEC Form 8-K] [Lexaria Bioscience Corp. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/lexaria-bioscience-corp-filed-sec-form-8-k-other-events-6684760)
- 2026-08-13 13:00 UTC [Market Insight] [Lexaria Enters a Material Transfer Agreement With PegBio](https://www.quantisnow.com/insight/lexaria-enters-a-material-transfer-agreement-with-pegbio-6679593)
- 2026-08-10 21:00 UTC [SEC Form 8-K] [Lexaria Bioscience Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/lexaria-bioscience-corp-filed-sec-form-8-k-notice-of-delisting-6674214)
- 2026-07-30 16:02 UTC [SEC Form 8-K] [Lexaria Bioscience Corp. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/lexaria-bioscience-corp-filed-sec-form-8-k-material-modification-to-6655651)
- 2026-07-30 15:00 UTC [Market Insight] [Lexaria Announces Effective Date for Reverse Stock Split](https://www.quantisnow.com/insight/lexaria-announces-effective-date-for-reverse-stock-split-6655471)
- 2026-07-13 20:23 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Lexaria Bioscience Corp.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-lexaria-bioscience-corp-6635459)
- 2026-07-06 13:10 UTC [Market Insight] [Lexaria Updates Business Development](https://www.quantisnow.com/insight/lexaria-updates-business-development-6627551)
- 2026-06-25 13:10 UTC [Market Insight] [Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule](https://www.quantisnow.com/insight/lexarias-human-study-glp-1-h26-7-has-begun-dosing-on-schedule-6615397)
- 2026-06-23 13:25 UTC [Market Insight] [Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule](https://www.quantisnow.com/insight/lexarias-animal-study-glp-1-a26-1-has-begun-dosing-on-schedule-6612122)
- 2026-06-17 13:25 UTC [Market Insight] [GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand](https://www.quantisnow.com/insight/glp-1-arms-race-intensifies-as-the-addressable-markets-continue-to-6606144)
- 2026-06-09 13:25 UTC [Market Insight] [Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway](https://www.quantisnow.com/insight/lexarias-animal-study-examining-next-generation-glp-1-drugs-is-underway-6594855)
- 2026-06-03 13:25 UTC [Market Insight] [Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program](https://www.quantisnow.com/insight/lexaria-attending-the-bio-international-convention-as-part-of-a-6586173)
- 2026-05-19 13:15 UTC [Market Insight] [Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7](https://www.quantisnow.com/insight/lexaria-receives-independent-review-board-approval-to-begin-human-pilot-6562020)
- 2026-05-07 13:25 UTC [Market Insight] [Lexaria Bioscience Releases Second Episode of Investor Video Series](https://www.quantisnow.com/insight/lexaria-bioscience-releases-second-episode-of-investor-video-series-6538008)
- 2026-05-05 13:10 UTC [Market Insight] [Lexaria Updates Progress on Human Study #7](https://www.quantisnow.com/insight/lexaria-updates-progress-on-human-study-7-6531175)
- 2026-05-01 13:25 UTC [Market Insight] [Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications](https://www.quantisnow.com/insight/lexaria-bioscience-launches-ongoing-investor-video-series-to-expand-shareholder-6526145)
- 2026-04-29 13:10 UTC [Market Insight] [Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended](https://www.quantisnow.com/insight/material-transfer-agreement-between-pharmaceutical-company-and-lexaria-is-extended-6520478)
- 2026-04-23 13:05 UTC [Market Insight] [Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs](https://www.quantisnow.com/insight/lexaria-launches-new-study-to-examine-next-generation-glp-1-drugs-6511982)
- 2026-04-21 13:10 UTC [Market Insight] [Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales](https://www.quantisnow.com/insight/lexaria-expects-oral-glp-1-pills-to-generate-billions-in-new-6507958)
- 2026-04-15 13:10 UTC [Market Insight] [Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property](https://www.quantisnow.com/insight/lexarias-new-animal-study-aims-to-expand-valuable-intellectual-property-6500780)
- 2026-04-13 17:07 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Lexaria Bioscience Corp.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-lexaria-bioscience-corp-6497651)
- 2026-04-07 13:10 UTC [Market Insight] [Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval](https://www.quantisnow.com/insight/lexaria-applauds-eli-lillys-foundayotm-drug-approval-6490725)
- 2026-04-01 13:20 UTC [Market Insight] [Lexaria to Begin New Human Clinical Study in GLP-1](https://www.quantisnow.com/insight/lexaria-to-begin-new-human-clinical-study-in-glp-1-6481183)
- 2026-03-26 13:20 UTC [Market Insight] [Lexaria's Robust Patent Portfolio Continues to Grow](https://www.quantisnow.com/insight/lexarias-robust-patent-portfolio-continues-to-grow-6470336)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/LEXX
- Earnings history: https://www.quantisnow.com/earnings/LEXX
- Dividend history: https://www.quantisnow.com/dividends/LEXX
- Insider transactions: https://www.quantisnow.com/insiders/LEXX
- Options chain: https://www.quantisnow.com/options/LEXX
- SEC 8-K filings only: https://www.quantisnow.com/company/LEXX/8-k
- RSS and alerts for LEXX: https://www.quantisnow.com/docs/rss-feeds.md
